Your activity: 2 p.v.

Sufentanil: Drug information

Sufentanil: Drug information
(For additional information see "Sufentanil: Patient drug information" and see "Sufentanil: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Accidental exposure and Risk Evaluation and Mitigation Strategy (REMS) program (sublingual tablet):

Accidental exposure to or ingestion of sufentanil, especially in children, can result in respiratory depression and death. Because of the potential for life-threatening respiratory depression due to accidental exposure, sufentanil is only available through a restricted program called the Dsuvia REMS Program. Sufentanil must only be dispensed to patients in a certified medically supervised health care setting. Discontinue use of sufentanil prior to discharge or transfer from the certified medically supervised health care setting.

Life-threatening respiratory depression (sublingual tablet):

Serious, life-threatening, or fatal respiratory depression may occur with use of sufentanil. Monitor for respiratory depression, especially during initiation of sufentanil.

Addiction, abuse, and misuse:

Sufentanil exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly for these behaviors and conditions.

Cytochrome P450 3A4 interaction (sublingual tablet):

The concomitant use of sufentanil with all cytochrome P450 3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in sufentanil plasma concentration. Monitor patients receiving sufentanil and any CYP3A4 inhibitor or inducer.

Risks from concomitant use with benzodiazepines or other CNS depressants (sublingual tablet):

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Brand Names: US
  • Dsuvia
Pharmacologic Category
  • Analgesic, Opioid;
  • Anilidopiperidine Opioid;
  • General Anesthetic
Dosing: Adult
Acute pain management

Acute pain management: Sublingual tablet: Initial: Sublingual: 30 mcg; may repeat as needed with a minimum of 1 hour between doses; maximum dose: 360 mcg/day (12 tablets); do not use for >72 hours

Note: Only administer in a certified medically supervised health care setting by a health care provider; discontinue treatment prior to discharge from supervised setting.

Surgical analgesia

Surgical analgesia:

Surgical analgesia (as a component of balanced anesthesia) (surgery expected to last: 1 to 2 hours): IV: Total dose: 1 to 2 mcg/kg with N2O/O2; ≥75% of total dose may be administered by slow injection or infusion prior to intubation (titrate to individual response)

Maintenance:

Incremental dosing: According to the manufacturer, 10 to 25 mcg may be administered as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. May also administer doses in the range of 5 to 20 mcg as needed (Barash 2009) or 0.1 to 0.25 mcg/kg as needed (Miller 2010). Total dose should not exceed 1 mcg/kg/hour of expected surgical time.

Continuous infusion: May also be administered as a continuous infusion with the infusion rate based on the induction dose used. Maximum infusion rate according to the manufacturer: 1 mcg/kg/hour. May also administer doses in the range of 0.3 to 0.9 mcg/kg/hour (Barash 2009) or 0.5 to 1.5 mcg/kg/hour (Miller 2010).

Surgical analgesia (as a component of balanced anesthesia) (surgery expected to last 2 to 8 hours): Total dose: 2 to 8 mcg/kg with N2O/O2; ≤75% of total dose may be administered by slow injection or infusion prior to intubation (titrate to individual response).

Maintenance:

Incremental dosing: According to the manufacturer, 10 to 50 mcg may be administered as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. Total dose should not exceed 1 mcg/kg/hour of expected surgical time.

Continuous infusion: May also be administered as a continuous infusion with the infusion rate based on the induction dose used. Maximum infusion rate according to the manufacturer: 1 mcg/kg/hour. May also administer doses in the range of 0.3 to 0.9 mcg/kg/hour (Barash, 2009) or 0.5 to 1.5 mcg/kg/hour (Miller, 2010).

Surgical anesthesia

Surgical anesthesia: Total dose: 8 to 30 mcg/kg as a slow injection, infusion, or injection followed by infusion; titrate to individual patient response. Note: In patients administered high doses of sufentanil, qualified personnel and adequate facilities are necessary to manage the potential for postoperative respiratory depression.

Maintenance:

Incremental dosing: 0.5 to 10 mcg/kg as needed in anticipation of surgical stress

Continuous infusion: Base infusion rate on the induction dose so that the total dose for the procedure does not exceed 30 mcg/kg

Analgesia for labor and delivery

Analgesia for labor and delivery: Epidural: 10 to 15 mcg with bupivacaine 0.125% with/without epinephrine. Dose can be repeated twice (for a total of 3 doses) at not less than 1-hour intervals until delivery.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression.

Dosing: Pediatric

(For additional information see "Sufentanil: Pediatric drug information")

Note: Doses should be titrated to appropriate effects; wide range of doses, dependent upon patient age (particularly young infants), desired degree of analgesia or anesthesia; use lean body weight to dose patients who are >20% above ideal body weight. Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics.

Cardiac surgery anesthesia

Cardiac surgery anesthesia: Infants, Children, and Adolescents: IV: Initial: 5 to 25 mcg/kg; repeat maintenance doses: 1 to 5 mcg/kg/doses up to 25 to 50 mcg/dose as needed based on response to initial dose and as determined by changes in vital signs indicating surgical stress or lightening of anesthesia; data based on experience in cardiac surgery, which requires much higher induction and maintenance doses; lower dosing may be sufficient for other procedures (Coté 2013; Moore 1985).

Epidural

Epidural: Limited data available: Infants ≥3 months and Children: Epidural injection: Initial bolus: 0.2 mcg/kg followed by continuous infusion at 0.1 mcg/kg/hour in combination with ropivacaine (Woloszczuk-Gebicka 2014)

Procedural/preoperative sedation

Procedural/preoperative sedation: Limited data available: Children ≥3 years: Intranasal: 1 to 3 mcg/kg in combination with other agents (Bayrak 2007; Coté 2013; Henderson 1988; Hitt 2014; Lundeberg 2011; Roelofse 2004)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression. A case-series evaluation of six pediatric patients (age range: 10 to 15 years) with chronic renal failure undergoing transplantation did not show overall differences in pharmacokinetic parameters compared to normal renal function; however, amongst the pediatric patients, a high degree of variability was observed; dosing should be individualized (Davis 1988)

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression.

Dosing: Older Adult

Refer to adult dosing. Use with caution and titrate slowly; monitor closely for signs of CNS and respiratory depression.

Dosing: Obesity: Adult

IV: In adult obese patients (eg, >20% above ideal body weight), use lean body weight to determine dosage.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Generic: 50 mcg/mL (1 mL); 100 mcg/2 mL (2 mL); 250 mcg/5 mL (5 mL)

Tablet Sublingual, Sublingual, as citrate:

Dsuvia: 30 mcg [contains fd&c blue #2 (indigotine)]

Generic Equivalent Available: US

May be product dependent

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 50 mcg/mL (1 mL, 5 mL)

Controlled Substance

C-II

Administration: Adult

IV: Intermittent doses may be administered IV as either a slow injection (eg, over at least 2 minutes [Sebel 1982] or a range of 2 to 10 minutes [Miller 2010]) or as an infusion. May also be administered as a continuous infusion.

Oral: Sublingual tablet: Administer by a health care provider in a certified medically supervised health care setting only. Wear gloves when administering. Tablet is packaged in a single-dose applicator; do not open until ready to administer. Patient should open their mouth and touch their tongue to roof of mouth. Using the single-dose applicator, administer into sublingual space. Patient should not chew or swallow tablet; do not eat or drink and minimize talking for 10 minutes after administration. Refer to manufacturer’s labeling for additional information.

Administration: Pediatric

Parenteral: IV: Administer at a concentration ≤ 50 mcg/mL (undiluted)

Intermittent IV: May be administered by either slow injection or as an infusion.

Slow IV injection: Administer over at least 2 minutes (Moore 1985; Sebel 1982); in adults, a range of 2 to 10 minutes has been used (Miller 2010).

Continuous IV infusion: Administer as a continuous infusion via an infusion pump

Intranasal: Administer using a needleless syringe over 15 to 20 seconds (Henderson 1988) or by a nasal actuating device (eg, GoMedical Nasal Device or MAD nasal drug delivery device) (Hitt 2014; Roelofse 2004)

Use: Labeled Indications

Acute pain management (sublingual tablet): Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Limitations of use: Reserve for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Administer by health care provider in a health care setting (eg, hospital, surgical center, emergency department) only; not for home use. Do not administer >72 hours (has not been studied).

Epidural analgesia (injection): For epidural administration as an analgesic combined with low-dose bupivacaine during labor and vaginal delivery.

Surgical analgesia (injection): Analgesic adjunct for the maintenance of balanced general anesthesia in patients who are intubated and ventilated.

Surgical anesthesia (injection): As a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures; in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position; to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.

Medication Safety Issues
Sound-alike/look-alike issues:

SUFentanil may be confused with alfentanil, fentaNYL

Sufenta may be confused with Alfenta, Sudafed, Survanta

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Central nervous system: Headache (12%)

Dermatologic: Pruritus (epidural administration with bupivacaine: 25%)

Gastrointestinal: Nausea (29%)

1% to 10%:

Cardiovascular: Hypotension (5%)

Central nervous system: Dizziness (6%)

Gastrointestinal: Vomiting (6%)

Frequency not defined:

Cardiovascular: Bradycardia, ECG abnormality, flushing, hypertension, orthostatic hypotension, oxygen saturation decreased, peripheral vasodilation, presyncope, sinus tachycardia, syncope

Central nervous system: Agitation, anxiety, confusion, disorientation, drowsiness, drug abuse, drug dependence, euphoria, hallucination, insomnia, lethargy, memory impairment, mental status changes, sedation

Dermatologic: Hyperhidrosis, skin rash

Gastrointestinal: Abdominal distension, abdominal distress, constipation, decreased gastrointestinal motility, diarrhea, dyspepsia, eructation, flatulence, gastritis, hiccups, intestinal obstruction (postoperative), oral hypoesthesia, retching, upper abdominal pain, xerostomia

Genitourinary: Decreased urine output, oliguria, urinary hesitancy, urinary retention

Hepatic: Increased liver enzymes, increased serum aspartate aminotransferase

Neuromuscular & skeletal: Muscle rigidity, muscle spasm

Ophthalmic: Miosis

Renal: Renal failure syndrome

Respiratory: Apnea, atelectasis, bradypnea, hypoventilation, hypoxia, respiratory depression, respiratory distress, respiratory failure

<1%, postmarketing, and/or case reports: Anaphylaxis

Contraindications

Hypersensitivity (eg, anaphylaxis) to sufentanil or any component of the formulation

Additional contraindications for sublingual tablets: Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to fentanyl or other morphinomimetics; IV use during labor or before clamping cord during cesarean section; epidural administration in patients with severe hemorrhage or shock, septicemia, or infection at proposed puncture site

Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).

• Bradyarrhythmias: Severe bradycardia may occur; use with caution in patients with bradyarrhythmias.

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Use injection with caution in patients with circulatory shock. Avoid use of sublingual tablets in patients with circulatory shock.

• Respiratory depression: [US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur with use of sufentanil. Monitor for respiratory depression, especially during initiation of sufentanil or dose escalation. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. Patients and caregivers should be educated on how to recognize respiratory depression and the importance of getting emergency assistance immediately (eg, calling 911) in the event of known or suspected overdose.

• Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of sufentanil and serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, 5-HT receptor antagonists, mirtazapine, trazodone, tramadol) and agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile BP, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue sufentanil if serotonin syndrome is suspected.

Disease-related concerns:

• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. Use of sublingual tablets is contraindicated with known or suspected GI obstruction, including paralytic ileus.

• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; opioids may cause constriction of sphincter of Oddi.

• CNS depression/coma: Use with caution in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO2 retention.

• Delirium tremens: Use opioids with caution in patients with delirium tremens.

• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.

• Hepatic impairment: Use with caution and reduce dose as needed in patients with hepatic impairment.

• Obesity: Use with caution in patients who are morbidly obese. Consider use of lean body weight for dosing in patients >20% over ideal body weight.

• Prostatic hyperplasia/urinary stricture: Use opioids with caution in patients with prostatic hyperplasia and/or urinary stricture.

• Psychosis: Use opioids with caution in patients with toxic psychosis.

• Renal impairment: Use with caution and reduce dose as needed in patients with renal impairment.

• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages.

• Seizures: Use with caution in patients with a history of seizure disorders; may increase risk or exacerbate preexisting seizure disorders.

• Sleep-related disorders: Opioid use increases the risk for sleep-related disorders (eg, central sleep apnea, hypoxemia) in a dose-dependent fashion; use with caution.

• Thyroid dysfunction: Use opioids with caution in patients with thyroid dysfunction.

Concurrent drug therapy issues:

• Benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in hypotension, profound sedation, respiratory depression, coma, and death. Following the administration of sufentanil, the dose of other CNS depressant drugs should be reduced. Consider prescribing naloxone for emergency treatment of opioid overdose in patients taking benzodiazepines or other CNS depressants concomitantly with opioids.

• CYP3A4 interactions: Use with all CYP3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitant CYP3A4 inducer may result in increased sufentanil concentrations. Monitor patients receiving sufentanil and any CYP3A4 inhibitor or inducer.

Special populations:

• Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.

• Older adult: Use with caution in elderly patients; may be more sensitive to adverse effects.

• Neonates: Neonatal opioid withdrawal syndrome: Prolonged use of opioids during pregnancy can cause neonatal opioid withdrawal syndrome in the newborn, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. Observe newborns for signs and symptoms of neonatal opioid withdrawal syndrome. Signs and symptoms include irritability, hyperactivity, and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

• Pediatric: Use caution in neonates as clearance of sufentanil is much slower than adults; neonates with cardiovascular disease have an even slower clearance. The clearance of sufentanil in children 2 to 8 years of age was shown to be twice as rapid as that seen in adults and adolescents (Lundeberg 2011).

Other warnings/precautions:

• Abuse/misuse/diversion: [US Boxed Warning]: Sufentanil exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing sufentanil and monitor all patients regularly for the development of these behaviors and conditions. Use with caution in patients with a personal or family history of drug abuse or acute alcoholism or mental illness; potential for drug dependency exists.

• Accidental exposure (sublingual tablet): [US Boxed Warning]: Accidental exposure to or ingestion of sufentanil, especially in children, can result in respiratory depression and death.

• Appropriate use: Epidural: Proper placement of the needle or catheter in the epidural space should be verified before injection to assure that unintentional intravascular or intrathecal administration does not occur. Unintentional intravascular injection may result in a potentially serious overdose, including acute truncal muscular rigidity and apnea. Unintentional intrathecal injection of the full sufentanil/bupivacaine epidural doses and volume may produce effects of high spinal anesthesia, including prolonged paralysis and delayed recovery.

• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of), or have experienced a previous opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help (FDA 2020).

• Rapid infusion: Injection: Inject slowly over at least 2 minutes (Sebel 1982); rapid IV infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.

• REMS program (sublingual tablet): [US Boxed Warning]: Because of the potential for life-threatening respiratory depression due to accidental exposure, sufentanil is only available through a restricted program called the REMS Program. Sufentanil must only be dispensed to patients in a certified medically supervised health care setting. Discontinue use of sufentanil prior to discharge or transfer from the certified medically supervised health care setting. Information about the REMS program is available by calling 1-855-925-8476 or at www.DSUVIAREMS.com.

• Trained individuals: Injection: Sufentanil should be administered by health care providers specifically trained in the use of anesthetic agents and should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Risk D: Consider therapy modification

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider therapy modification

Amphetamines: May enhance the analgesic effect of Opioid Agonists. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk X: Avoid combination

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Risk D: Consider therapy modification

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

CYP3A4 Inducers (Strong): May decrease the serum concentration of SUFentanil. Management: If a strong CYP3A4 inducer is initiated in a patient on sufentanil, consider a sufentanil dose increase and monitor for decreased sufentanil effects and opioid withdrawal symptoms. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Strong): May increase the serum concentration of SUFentanil. Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression). Risk D: Consider therapy modification

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. Risk C: Monitor therapy

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. Risk C: Monitor therapy

Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. Risk X: Avoid combination

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod. Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose. Risk D: Consider therapy modification

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. Risk C: Monitor therapy

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products. Risk C: Monitor therapy

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: SUFentanil may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression. Risk X: Avoid combination

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nalfurafine: Opioid Agonists may enhance the adverse/toxic effect of Nalfurafine. Opioid Agonists may diminish the therapeutic effect of Nalfurafine. Risk C: Monitor therapy

Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required. Risk D: Consider therapy modification

Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations. Risk X: Avoid combination

Nefazodone: Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4). Management: If concomitant use of opioid agonists that are metabolized by CYP3A4 and nefazodone is necessary, consider dose reduction of the opioid until stable drug effects are achieved. Monitor for increased opioid effects and serotonin syndrome/serotonin toxicity. Risk D: Consider therapy modification

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations. Risk X: Avoid combination

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. Risk C: Monitor therapy

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

PHENobarbital: May enhance the CNS depressant effect of SUFentanil. PHENobarbital may decrease the serum concentration of SUFentanil. Management: Avoid use of sufentanil and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased sufentanil efficacy and withdrawal if combined. Risk D: Consider therapy modification

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod. Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm. Risk D: Consider therapy modification

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Primidone: May enhance the CNS depressant effect of SUFentanil. Primidone may decrease the serum concentration of SUFentanil. Management: Avoid use of sufentanil and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased sufentanil efficacy and withdrawal if combined. Risk D: Consider therapy modification

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Samidorphan: May diminish the therapeutic effect of Opioid Agonists. Risk X: Avoid combination

Serotonergic Agents (High Risk): Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring. Risk D: Consider therapy modification

Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. Risk C: Monitor therapy

Succinylcholine: May enhance the bradycardic effect of Opioid Agonists. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Reproductive Considerations

Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction or infertility in men and women (Brennan 2013).

Pregnancy Considerations

Sufentanil crosses the placenta (Cuypers 1995; Loftus 1995).

According to some studies, maternal use of opioids may be associated with birth defects (including neural tube defects, congenital heart defects, and gastroschisis), poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). Opioids used as part of obstetric analgesia/anesthesia during labor and delivery may temporarily affect the fetal heart rate (ACOG 209 2019).

Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Opioids may cause respiratory depression and psychophysiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.

Sufentanil injection is commonly used to treat maternal pain during labor and immediately postpartum (ACOG 209 2019). Administration of epidural sufentanil with bupivacaine with or without epinephrine is indicated for use in labor and delivery. Sufentanil tablets are not recommended for use during or immediately before labor.

The ACOG recommends that pregnant women should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).

Breastfeeding Considerations

Sufentanil is present in breast milk.

Sufentanil concentrations in breast milk were evaluated in 29 women undergoing elective cesarean delivery. All women received epidural sufentanil 20 mcg with bupivacaine; 11 women also received additional sufentanil via patient controlled epidural analgesia (PCEA). Breast milk was sampled on days 1, 2, and 3 following surgery. Sufentanil was detected in breast milk obtained on all 3 days; however, not all women provided samples and sufentanil was not present in every sample obtained. Sufentanil breast milk concentrations were greater than those in the maternal plasma in all samples. The highest concentrations were on day 3 in women using PCEA. Adverse events were not observed in the newborns (Cuypers 1995). Sufentanil was not detected in the colostrum of nine women who received a single epidural dose of 50 mcg prior to elective cesarean delivery; sampling occurred ~1 hour after sufentanil administration (Madej 1987).

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant. In general, a single occasional dose of an opioid analgesic may be compatible with breastfeeding (WHO 2002). Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ABM [Reece-Stremtan 2017]; ACOG 209 2019; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped.

The Academy of Breast Feeding Medicine recommends postponing elective surgery until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]).

Monitoring Parameters

Pain relief, respiratory and cardiovascular status, blood pressure, and heart rate

Mechanism of Action

Binds to opioid receptors throughout the CNS. Once receptor binding occurs, effects are exerted by opening K+ channels and inhibiting Ca++ channels. These mechanisms increase pain threshold, alter pain perception, inhibit ascending pain pathways; short-acting opioid; dose-related inhibition of catecholamine release (up to 30 mcg/kg) controls sympathetic response to surgical stress.

Pharmacokinetics

Onset of action: Analgesia: IV: 1 to 3 minutes; Epidural: 10 minutes; Sublingual tablets: ~30 minutes (Fisher 2018).

Duration: Dose dependent: Anesthesia adjunct doses:

IV: Context-sensitive half-time and recovery varies depending on dose, duration of administration, concomitant anesthesia, and other clinical factors (Miller 2015).

Epidural: 10 to 15 mcg with bupivacaine 0.125%: 1.7 hours.

Sublingual tablets: ~3 hours (Fisher 2018).

Distribution: Vdss: Children 2 to 8 years of age: 2.9 ± 0.6 L/kg; Adults: 1.7 ± 0.2 L/kg.

Protein binding: Neonates: 79%; Adults: 91% to 93%; primarily to alpha 1-acid glycoprotein.

Metabolism: Primarily hepatic and small intestine via demethylation and dealkylation.

Bioavailability: Sublingual tablet: ~53%.

Half-life elimination:

IV: Neonates: 7.2 ± 2.7 hours; Infants and Children (2 to 8 years of age): 97 ± 42 minutes; Adolescents 10 to 15 years of age: 76 ± 33 minutes; Adults: 164 minutes.

Sublingual tablet: 2.5 ± 0.85 hours (Fisher 2018).

Time to peak: Sublingual tablet: 1 hour.

Excretion: Urine (2% excreted as unchanged drug; 80% metabolites) within 24 hours.

Clearance:

Children 2 to 8 years: 30.5 ± 8.8 mL/minute/kg.

Adolescents: 12.8 ± 12 mL/minute/kg.

Adults: 12.7 ± 0.8 mL/minute/kg.

Pricing: US

Solution (SUFentanil Citrate Intravenous)

50 mcg/mL (per mL): $5.38 - $7.09

100 mcg/2 mL (per mL): $4.55 - $4.89

250 mcg/5 mL (per mL): $3.48 - $3.84

Sublingual (Dsuvia Sublingual)

30 mcg (per each): $88.48

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Disufen (IT);
  • Dzuveo (AT, BE, CZ, EE, HR, LT, LV, NL, PL, PT);
  • Fastfen (BR);
  • Fentafienil (IT);
  • Sofentil (RO);
  • Sufenta (AR, AT, BE, BR, CH, CL, CZ, DK, FI, FR, HR, ID, IS, LU, NL, NO, PT, SA, SE, SI, TR, TW, UY, ZA);
  • Sufenta Forte (LB, SA);
  • Sufental (KR);
  • Zalviso (BE, CZ, DE, EE, HR, IE, LT, LV, NL, PT);
  • Zuftil (CR, DO, GT, HN, MX, NI, PA, SV)


For country code abbreviations (show table)
  1. American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. Obstet Gynecol. 2019;133(4):e285-e286. [PubMed 30913200]
  2. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. Obstet Gynecol. 2019;133(3):e208-e225. [PubMed 30801474]
  3. American Pain Society (APS). "Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain," 6th ed. Glenview, IL: American Pain Society, 2008.
  4. Anand KJ and Hickey PR, "Halothane-Morphine Compared With High-Dose Sufentanil for Anesthesia and Postoperative Analgesia in Neonatal Cardiac Surgery," N Engl J Med, 1992, 326(1):1-9. [PubMed 1530752]
  5. Barash PG, Cullen BF, Stoelting RK, Cahalan M, Stock C, eds. Clinical Anesthesia. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
  6. Bayrak F, Gunday I, Memis D, Turan A. A comparison of oral midazolam, oral tramadol, and intranasal sufentanil premedication in pediatric patients. J Opioid Manag. 2007;3(2):74-78. [PubMed 17520986]
  7. Bovill JG, Sebel PS, Blackburn CL, et al, “The Pharmacokinetics of Sufentanil in Surgical Patients,” Anesthesiology, 1984, 61(5):502-6. [PubMed 6238552]
  8. Bowdle TA, “Myoclonus Following Sufentanil Without EEG Seizure Activity,” Anesthesiology, 1987, 67(4):593-5. [PubMed 2959172]
  9. Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001. [PubMed 23414717]
  10. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130. [PubMed 19187889]
  11. Coté CJ, Lerman J, Anderson B, eds. A Practice of Anesthesia for Infants and Children. 5th ed. Philadelphia, PA: Saunders Elsevier; 2013.
  12. Cuypers L, Wiebalck A, Vertommen JD, et al. Epidural sufentanil for postcesarean pain: breast milk levels and effects on the baby. Acta Aneasthiol Belg. 1995;46:104-105.
  13. Davis PJ, Stiller RL, Cook DR, et al. Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. Anesth Analg. 1988;67(3):268-271. [PubMed 2964213]
  14. Dow K, Ordean A, Murphy-Oikonen J, et al; Neonatal Abstinence Syndrome Work Group. Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol. 2012;19(3):488-506. [PubMed 23241498]
  15. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016 [published correction appears in MMWR Recomm Rep. 2016;65(11):295]. MMWR Recomm Rep. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1. [PubMed 26987082]
  16. Dsuvia (sufentanil) sublingual tablet [prescribing information]. Hayward, CA: AcelRx Pharmaceuticals Inc; May 2021.
  17. Fisher DM, Chang P, Wada DR, Dahan A, Palmer PP. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. Anesthesiology. 2018;128(5):943-952. doi: 10.1097/ALN.0000000000002145. [PubMed 29498947]
  18. Guay J, Gaudreault P, Tang A, et al, “Pharmacokinetics of Sufentanil in Normal Children,” Can J Anaesth, 1992, 39(1):14-20. [PubMed 1531117]
  19. Gust R and Böhrer H, “Stiff-Man Syndrome Associated With Continuous Sufentanil Administration,” Anaesthesia, 1995, 50(6):575. [PubMed 7618699]
  20. Henderson JM, Brodsky DA, Fisher DM, Brett CM, Hertzka RE. Pre-induction of anesthesia in pediatric patients with nasally administered sufentanil. Anesthesiology. 1988;68(5):671-675. [PubMed 2897172]
  21. Hitt JM, Corcoran T, Michienzi K, Creighton P, Heard C. An evaluation of intranasal sufentanil and dexmedetomidine for pediatric dental sedation. Pharmaceutics. 2014;6(1):175-184. [PubMed 24662315]
  22. Hudak ML, Tan RC; Committee On Drugs, Committee on Fetus and Newborn, American Academy of pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):540-560. [PubMed 22291123]
  23. Loftus JR, Hill H, Cohen SE. Placental transfer and neonatal effects of epidural sufentanil and fentanyl administered with bupivacaine during labor. Anesthesiology. 1995;83(2):300-308. [PubMed 7631952]
  24. Lundeberg S, Roelofse JA. Aspects of pharmacokinetics and pharmacodynamics of sufentanil in pediatric practice. Pediatr Anaesth. 2011;21:274-279. [PubMed 20849451]
  25. Madej TH, Strunin L. Comparison of epidural fentanyl with sufentanil. Analgesia and side effects after a single bolus dose during elective caesarean section. Anaesthesia. 1987;42(11):1156-1161. [PubMed 2963561]
  26. Miller RD. Miller’s Anesthesia. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.
  27. Miller RD. Miller’s Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015.
  28. Moore RA, Yang SS, McNicholas KW, Gallagher JD, Clark DL. Hemodynamic and anesthetic effects of sufentanil as the sole anesthetic for pediatric cardiovascular surgery. Anesthesiology. 1985;62(6):725-731. [PubMed 3159311]
  29. Nguyen The Tich S, Vecchierini MF, Debillon T, et al, "Effects of Sufentanil on Electroencephalogram in Very and Extremely Preterm Neonates," Pediatrics, 2003, 111(1):123-8. [PubMed 12509564]
  30. Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. Breastfeed Med. 2017;12(9):500-506. [PubMed 29624435]
  31. Roelofse JA, Shipton EA, de la Harpe CJ, Blignaut RJ. Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison. Anesth Prog. 2004;51(4):114-121. [PubMed 15675259]
  32. Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3):e796-e809. [PubMed 23979084]
  33. Scholz J, Steinfath M, and Schulz M, “Clinical Pharmacokinetics of Alfentanil, Fentanyl, and Sufentanil. An Update,” Clin Pharmacokinet, 1996, 31(4):275-92. [PubMed 8896944]
  34. Seguin JH, Erenberg A, and Leff RD, “Safety and Efficacy of Sufentanil Therapy in the Ventilated Infant,” Neonatal Netw, 1994, 13(4):37-40. [PubMed 8007923]
  35. Sebel PS, Bovil JG. Cardiovascular effects of sufentanil anesthesia. Anesth Analg. 1982;61(2):115-119. [PubMed 6119930]
  36. Starr NJ, Sethna DH, Estafanous FG. Bradycardia and asystole following the rapid administration of sufentanil with vecuronium. Anesthesiology. 1986;64(4):521-523. [PubMed 2870669]
  37. Sufenta (sufentanil citrate) [prescribing information]. Lake Forest, IL: Akorn Inc; December 2008.
  38. Sufentanil Citrate [prescribing information]. Lake Forest, IL: Akorn Inc; October 2019.
  39. Sufentanil Citrate [product monograph]. Mississauga, Ontario, Canada: SteriMax Inc; June 2015.
  40. US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain. Published July 23, 2020. Accessed September 18, 2020.
  41. Woloszczuk-Gebicka B, Grabowski T, Borucka B, Karas-Trzeciak M. Pharmacokinetics of sufentanil administered with 0.2% ropivacaine as a continuous epidural infusion for postoperative pain relief in infants. Paediatr Anaesth. 2014;24(9):962-967. [PubMed 24824135]
  42. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://apps.who.int/medicinedocs/pdf/s5406e/s5406e.pdf
Topic 9954 Version 316.0